drugset / Trial / NCT00730665

Efficacy And Safety Of PF-00885706 For The Relief Of Symptoms In Subjects With Gastro-esophageal Reflux Disease (GERD)

NCT00730665

Phase 2 Terminated 81 enrolled Pfizer
RandomizedParallel-groupTriple-blindTreatment

Summary

To understand the dose-response characteristics of PF-00885706 for efficacy in terms of symptomatic relief when used as add-on treatment to esomeprazole 20mg (standard proton pump inhibitor \[PPI\] treatment), in subjects with gastro-esophageal reflux (GERD) who have inadequate relief with PPIs.

Timeline

Start
2008-01
Primary completion
2008-10
Completion
2008-10

Drugs

EvaluationDrugModalityDoseRoute
Subject PF-00885706 Unknown 100 ug
Subject PF-00885706 Unknown 300 ug
Subject PF-00885706 Unknown 1 mg
Subject PF-00885706 Unknown 3 mg
Comparator Esomeprazole Small molecule 20 mg